English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Genes in which germline mutations confer highly or moderately increased risks of cancer are called cancer predisposition genes (CPGs). Hereditary breast cancers occur in individuals with germline variants in various CPGs such as BRCA1, BRCA2, CHEK2, ATM, PALB2, TP53, PTEN, STK11, BRIP1, CDKN2A, BARD1, FANC1 . Multi-gene panel testing for detection of clinically actionable genetic variants in CPGs that are critical for cancer care is useful in routine clinical practice. This study aimed to describe the pattern of germline variants in a cohort of Sri Lankan patients referred for genetic evaluation of hereditary breast cancer to our centre. Methodology After providing pre-test counselling and obtaining written informed consent, blood samples from eleven individuals referred for genetic evaluation of hereditary breast cancer were tested using a 94-gene cancer panel test on the Illumina MiSeq NGS platform, followed by bioinformatics analysis. Results There were 9 (81.8%) patients with invasive carcinoma and 2 (18.2%) asymptomatic individuals. Their mean age was 47.4 years. Germline variants in seven CPGs were identified in 10 (90.9%) patients. The two most common variants were B RCA2 (27.3%)[c.9117G>A;p.Pro3039 =;c.784G>A; p.Ala262Thr;c.2488A>G;p.Asn830Asp] and BRCA1 (18.2%) c.823G>A;p.Gly275Ser; c.5289delG; p.Leu1764Terf]. The remaining variants were in moderate-penetrance genes: CHEK2 (9.1%) [c.1630G>A;p.Glu544Lys], ATM (9.1%) [c.2932T>C;p.Ser978Pro], PALB2 (9.1%) [c.2768T>G;p.Val923Gly], CDKN2A (9.1%) [c.377A>C;p.Gln126Pro] and FANC1 (9.1%) [c.3179T>C;p.Ile1060Thr]. Twenty percent were pathogenic variants, another 20% were likely pathogenic and 60% were variants of uncertain significance. Discussion Variants in both high-penetrance and moderate-penetrance genes associated with hereditary breast cancer were present in the patients tested. These risks would have been missed if testing were guided strictly by established single-gene and/or syndrome testing guidelines. Conclusion Identifying the underlying germline variants using multi-gene cancer panel testing is valuable in guiding treatment decisions and genetic counselling/screening of at-risk family members.

the journal of diagnostic pathology

Pattern of germline variants detected in Sri Lankan patients referred for genetic evaluation of hereditary breast cancer using a multi-gene cancer panel test